Literature DB >> 21523915

A roadmap for successful applications of clinical proteomics.

John P A Ioannidis1.   

Abstract

Despite over 30,000 publications on proteomics in the last decade, and the accumulation of extensive interesting information on the human proteome in diverse observations, the clinical translation of proteomics to-date has had major setbacks. I review here a roadmap for improving the success rate of clinical proteomics. The roadmap includes steps for improvements that need to be made in analytical tools, discovery, validation, clinical application, and post-clinical application appraisal. It is likely that most if not all of the components that are necessary for clinical success are either readily available, or should be possible to put in place with more rigorous research standards and concerted efforts of the research community, clinicians, and health agencies. Enthusiasm for the clinical impact of proteomics may need to be tempered currently until robust evidence can be obtained, but some clinical successes should eventually be feasible.
Copyright © 2011 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21523915     DOI: 10.1002/prca.201000096

Source DB:  PubMed          Journal:  Proteomics Clin Appl        ISSN: 1862-8346            Impact factor:   3.494


  10 in total

1.  Molecular-based diagnosis of multiple sclerosis and its progressive stage.

Authors:  Christopher Barbour; Peter Kosa; Mika Komori; Makoto Tanigawa; Ruturaj Masvekar; Tianxia Wu; Kory Johnson; Panagiotis Douvaras; Valentina Fossati; Ronald Herbst; Yue Wang; Keith Tan; Mark Greenwood; Bibiana Bielekova
Journal:  Ann Neurol       Date:  2017-11       Impact factor: 10.422

Review 2.  Promise, Progress, and Pitfalls in the Search for Central Nervous System Biomarkers in Neuroimmunological Diseases: A Role for Cerebrospinal Fluid Immunophenotyping.

Authors:  Bibiana Bielekova; Michael R Pranzatelli
Journal:  Semin Pediatr Neurol       Date:  2017-08-12       Impact factor: 1.636

Review 3.  Methods for Stratification and Validation Cohorts: A Scoping Review.

Authors:  Teresa Torres Moral; Albert Sanchez-Niubo; Anna Monistrol-Mula; Chiara Gerardi; Rita Banzi; Paula Garcia; Jacques Demotes-Mainard; Josep Maria Haro
Journal:  J Pers Med       Date:  2022-04-26

Review 4.  Opportunities and challenges for selected emerging technologies in cancer epidemiology: mitochondrial, epigenomic, metabolomic, and telomerase profiling.

Authors:  Mukesh Verma; Muin J Khoury; John P A Ioannidis
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-12-14       Impact factor: 4.254

Review 5.  Proteomics and metabolomics in renal transplantation-quo vadis?

Authors:  Rahul Bohra; Jacek Klepacki; Jelena Klawitter; Jost Klawitter; Joshua M Thurman; Uwe Christians
Journal:  Transpl Int       Date:  2012-11-21       Impact factor: 3.782

6.  Microvesicles/exosomes as potential novel biomarkers of metabolic diseases.

Authors:  Günter Müller
Journal:  Diabetes Metab Syndr Obes       Date:  2012-08-07       Impact factor: 3.168

7.  Implementation of proteomic biomarkers: making it work.

Authors:  Harald Mischak; John P A Ioannidis; Angel Argiles; Teresa K Attwood; Erik Bongcam-Rudloff; Mark Broenstrup; Aristidis Charonis; George P Chrousos; Christian Delles; Anna Dominiczak; Tomasz Dylag; Jochen Ehrich; Jesus Egido; Peter Findeisen; Joachim Jankowski; Robert W Johnson; Bruce A Julien; Tim Lankisch; Hing Y Leung; David Maahs; Fulvio Magni; Michael P Manns; Efthymios Manolis; Gert Mayer; Gerjan Navis; Jan Novak; Alberto Ortiz; Frederik Persson; Karlheinz Peter; Hans H Riese; Peter Rossing; Naveed Sattar; Goce Spasovski; Visith Thongboonkerd; Raymond Vanholder; Joost P Schanstra; Antonia Vlahou
Journal:  Eur J Clin Invest       Date:  2012-04-21       Impact factor: 4.686

8.  MALDI-TOF-MS analysis in discovery and identification of serum proteomic patterns of ovarian cancer.

Authors:  Agata Swiatly; Agnieszka Horala; Joanna Hajduk; Jan Matysiak; Ewa Nowak-Markwitz; Zenon J Kokot
Journal:  BMC Cancer       Date:  2017-07-06       Impact factor: 4.430

9.  Profiling of schizophrenia-associated serum peptides by MALDI-TOF-MS.

Authors:  Yingli Fu; Na Zhou; Yaqin Yu; Huiping Zhang; Yaoyao Sun; Mingyuan Zhang; Xin Chen; Yueying Wang; Qiong Yu
Journal:  J Neural Transm (Vienna)       Date:  2019-11-30       Impact factor: 3.575

10.  Detection and Identification of Serum Peptides Biomarker in Papillary Thyroid Cancer.

Authors:  Zhao-Lian Lu; Ying-Jian Chen; Xin-Yan Jing; Na-Na Wang; Ting Zhang; Cheng-Jin Hu
Journal:  Med Sci Monit       Date:  2018-03-17
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.